JTO Clinical and Research Reports最新文献

{"title":"Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L","authors":"Hideyuki Harada MD, PhD ,&nbsp;Akito Hata MD ,&nbsp;Masahiro Konno PhD ,&nbsp;Nobuaki Mamesaya MD, PhD ,&nbsp;Kiyoshi Nakamatsu MD, PhD ,&nbsp;Koji Haratani MD, PhD ,&nbsp;Takaya Yamamoto MD, PhD ,&nbsp;Ryota Saito MD, PhD ,&nbsp;Hiroshi Mayahara MD, PhD ,&nbsp;Masaki Kokubo MD, PhD ,&nbsp;Yuki Sato MD ,&nbsp;Nobuki Imano MD, PhD ,&nbsp;Takeshi Masuda PD, PhD ,&nbsp;Haruyuki Fukuda MD, PhD ,&nbsp;Toshikatsu Sado MD, PhD ,&nbsp;Kenichi Yoshimura PhD ,&nbsp;Yasumasa Nishimura MD, PhD ,&nbsp;Kazuhiko Nakagawa MD, PhD ,&nbsp;Isamu Okamoto MD, PhD ,&nbsp;Nobuyuki Yamamoto MD, PhD","doi":"10.1016/j.jtocrr.2025.100828","DOIUrl":"10.1016/j.jtocrr.2025.100828","url":null,"abstract":"<div><h3>Introduction</h3><div>Chemoradiotherapy (CRT) followed by durvalumab is the standard of care for unresectable locally advanced NSCLC. Limited prospective data have been reported on intensity-modulated radiotherapy (IMRT)–adapted CRT in the immunotherapy era.</div></div><div><h3>Methods</h3><div>In this multicenter prospective observational study, patients underwent IMRT-adapted CRT (platinum-doublet chemotherapy plus 60 Gy IMRT in 30 fractions under a prespecified radiation protocol), followed by consolidative durvalumab. The primary outcome was the durvalumab introduction rate within 42 days post-CRT.</div></div><div><h3>Results</h3><div>Thirty-two patients with unresectable locally advanced NSCLC were enrolled between November 2019 and February 2021. Among the 28 evaluable cases, durvalumab was introduced in 24 (85.7%, 90% confidence interval: 70.2%–95.0%) of 28 patients after CRT, achieving the primary end point. All 29 patients who received IMRT completed the scheduled 60 Gy radiotherapy dose. One year of durvalumab treatment was completed in 12 of 24 patients (50%). In the 24 patients who were durvalumab-introduced, the median progression-free survival and overall survival were 20.9 (95% confidence interval: 6.9–not evaluable) months and not reached, respectively. Two-year progression-free survival and overall survival rates were 44% and 73%, respectively. Among the 29 patients in the safety analysis set, there were no treatment-related deaths or grade 4 nonhematological adverse events. Pneumonitis grade 1 was observed in 13 patients (45%), grade 2 in seven (24%), and grade 3 in one (3%).</div></div><div><h3>Conclusions</h3><div>High durvalumab introduction rate was reported after the completion of IMRT-adapted CRT under a prespecified radiation protocol. Its efficacy has been suggested, with favorable safety profiles, including a low incidence of severe pneumonitis.</div></div><div><h3>Trial Registration</h3><div>University Hospital Medical Information Network database ID: UMIN000038366</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 6","pages":"Article 100828"},"PeriodicalIF":3.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to ‘Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research’ [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]","authors":"Cheol-Kyu Park MD, PhD ,&nbsp;Maryam Khalil BSc ,&nbsp;Nhu-An Pham PhD ,&nbsp;Stephanie Wong BSc ,&nbsp;Dalam Ly PhD ,&nbsp;Adrian Sacher MD, FRCPC ,&nbsp;Ming-Sound Tsao MD, FRCPC","doi":"10.1016/j.jtocrr.2025.100824","DOIUrl":"10.1016/j.jtocrr.2025.100824","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100824"},"PeriodicalIF":3.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy","authors":"Margaret Stalker MD ,&nbsp;Suzanne L. Walker PhD, CRNP, AOCN, BC ,&nbsp;Emily Lebow MD ,&nbsp;Emily Ling-Lin Pai MD, PhD ,&nbsp;Alex Watts MS ,&nbsp;Wei-Ting Hwang PhD ,&nbsp;Amir Banihashemi MD ,&nbsp;Evan Anderson MSN ,&nbsp;Leonid Roshkovan MD ,&nbsp;Sharyn I. Katz MD ,&nbsp;Leslie Litzky MD ,&nbsp;Andrew R. Haas MD, PhD ,&nbsp;Sunil Singhal MD ,&nbsp;Corey J. Langer MD ,&nbsp;Keith Cengel MD, PhD ,&nbsp;Melina E. Marmarelis MD, MSCE","doi":"10.1016/j.jtocrr.2025.100823","DOIUrl":"10.1016/j.jtocrr.2025.100823","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunotherapy (IO) has reported efficacy in pleural mesothelioma (PM). Brain metastases (BMs) in PM are rare; thus, surveillance brain imaging is not included in the guidelines. We evaluated the incidence of BM by treatment type.</div></div><div><h3>Methods</h3><div>In this retrospective analysis, patients with PM treated at the University of Pennsylvania between January 1, 2015, and August 31, 2023, were included. Demographic and clinical data were extracted from the medical records. The treatment categories included chemotherapy, single-agent IO, and dual-agent IO. A two-tailed Z score was used to determine a difference in the proportion of BM. Overall survival (OS) was analyzed using the Kaplan-Meier method. Of those with BM, available brain tissue was further analyzed.</div></div><div><h3>Results</h3><div>In total, 251 patients were included; the median age of the participants was 73 years (range: 35–92 y), 79% were male individuals, 91% were white, and 73% had epithelioid histology. In the study, 102 (40.6%) were treated with chemotherapy, 100 (39.8%) with single-agent IO, and 49 (19.5%) with dual-agent IO. The median OS (mOS) was 21.6 months (95% confidence interval: 17.7–25.5) and did not differ between treatment groups (<em>p</em> = 0.774). A higher proportion of patients treated with IO developed BM than those treated with chemotherapy (6/149 [4%] versus 0/102 [0%]; Z score <em>p</em> = 0.04). The mOS from BM diagnosis was 95 days (range: 16–1025 d). The histomorphology of three patients with available brain tissue were similar to the primary site and reported substantial edema and hemorrhage.</div></div><div><h3>Conclusions</h3><div>In this retrospective study, clinically significant BM was most prevalent in those exposed to IO and not seen in those receiving chemotherapy despite similar mOS between the groups. Brain imaging should be considered before starting IO in patients with PM.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100823"},"PeriodicalIF":3.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordant Response to Nivolumab Plus Ipilimumab and Identification of BRAF V600E Mutation in Biphasic Malignant Pleural Mesothelioma: Case Report","authors":"Olivia Wilkins DO ,&nbsp;Adedamola Omogbehin MD ,&nbsp;Peter J. Bergquist MD ,&nbsp;Chul Kim MD, MPH ,&nbsp;Stephen V. Liu MD ,&nbsp;Joshua E. Reuss MD","doi":"10.1016/j.jtocrr.2025.100820","DOIUrl":"10.1016/j.jtocrr.2025.100820","url":null,"abstract":"<div><div>Therapeutic advancement for malignant pleural mesothelioma (MPM) has been limited. Combination immunotherapy with nivolumab plus ipilimumab is a frontline treatment option for advanced MPM that is typically deployed for patients with sarcomatoid or biphasic MPM. Here, we present a case of biphasic MPM that exhibited a unique response pattern to first-line treatment with nivolumab plus ipilimumab, with brisk response in pleural and mediastinal sites of disease, but rapid progression in osseous/soft tissue sites of disease complicated by pathologic spinal cord compression. Pathologic findings from bony metastasis at progression found pure epithelioid histology without any evidence of sarcomatoid differentiation. Next-generation sequencing of this specimen revealed a <em>BRAF</em> V600E mutation, and the patient was subsequently treated with dabrafenib plus trametinib, achieving ongoing clinical and imaging response in all sites of the disease, including bones. This case supports the use of next-generation sequencing profiling in MPM, particularly in circumstances in which novel discordant response patterns are observed.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100820"},"PeriodicalIF":3.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902","authors":"Yoko Tsukita MD, PhD ,&nbsp;Rei Umezawa MD, PhD ,&nbsp;Taku Nakagawa MD, PhD ,&nbsp;Akira Anbai MD, PhD ,&nbsp;Tomonori Makiguchi MD, PhD ,&nbsp;Hisashi Tanaka MD, PhD ,&nbsp;Yosuke Horii MD, PhD ,&nbsp;Aya Suzuki MD ,&nbsp;Ryo Morita MD, PhD ,&nbsp;Hitomi Nogawa MD ,&nbsp;Hiroshi Yokouchi MD, PhD ,&nbsp;Nozomu Kimura MD, PhD ,&nbsp;Keiichi Jingu MD, PhD ,&nbsp;Akira Inoue MD, PhD ,&nbsp;Hisatoshi Sugiura MD, PhD ,&nbsp;Eisaku Miyauchi MD, PhD","doi":"10.1016/j.jtocrr.2025.100817","DOIUrl":"10.1016/j.jtocrr.2025.100817","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatment strategies that enhance the efficacy of immunotherapy are desired. Radiotherapy can enhance immunity, but the utility of adding radiotherapy to immunotherapy plus platinum-doubled chemotherapy in patients with metastatic NSCLC has not been explored.</div></div><div><h3>Methods</h3><div>This multicenter, single-arm phase 2 trial evaluated the efficacy and safety of combining radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic NSCLC. Patients begin receiving pembrolizumab plus platinum-doublet chemotherapy within 1 week of starting radiotherapy (30 Gy in 10 fractions). The primary end point was the 12-month progression-free survival (PFS) rate. The secondary end points included PFS, overall survival, and toxicity profiles.</div></div><div><h3>Results</h3><div>Forty patients were enrolled. In total, 37 and 38 patients were analyzed for efficacy and safety, respectively. The 12-month PFS rate was 44.3% (90% confidence interval [CI]: 30.3–57.3), which met the primary end point. The median PFS was 8.4 months (95% CI: 5.7–22.2), and the median overall survival was 30.1 months (95% CI: 22.3–not reached). Grade 3 or 4 adverse events occurred in 25 patients (65.8%), and one treatment-related death was reported. Pneumonitis was reported in 10 patients (26.3%), including two cases of grade 3 pneumonitis and one case of grade 5.</div></div><div><h3>Conclusions</h3><div>Adding radiotherapy to pembrolizumab plus platinum-doublet chemotherapy led to promising efficacy in patients with previously untreated metastatic NSCLC. Although caution should be exercised with regard to pneumonitis, adverse events were tolerable. Further research is needed to confirm the efficacy and safety of this strategy.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100817"},"PeriodicalIF":3.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment of Reviewers","authors":"","doi":"10.1016/S2666-3643(25)00026-8","DOIUrl":"10.1016/S2666-3643(25)00026-8","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 3","pages":"Article 100810"},"PeriodicalIF":3.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease","authors":"Carina M. Behr PhD ,&nbsp;Maarten J. IJzerman PhD ,&nbsp;Michelle M.A. Kip PhD ,&nbsp;Harry J.M. Groen MD, PhD ,&nbsp;Marjolein A. Heuvelmans MD, PhD ,&nbsp;Maarten van den Berge MD, PhD ,&nbsp;Pim van der Harst MD, PhD ,&nbsp;Marleen Vonder PhD ,&nbsp;Rozemarijn Vliegenthart MD, PhD ,&nbsp;Hendrik Koffijberg PhD","doi":"10.1016/j.jtocrr.2025.100813","DOIUrl":"10.1016/j.jtocrr.2025.100813","url":null,"abstract":"<div><h3>Introduction</h3><div>The conditional cost-effectiveness of low-dose computed tomography for lung cancer (LC) screening has been reported. Extending LC screening to chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), together with Big-3, could increase health benefits at marginal costs. This study aimed to estimate the cost-utility of Big-3 screening compared with no screening and LC screening in The Netherlands.</div></div><div><h3>Methods</h3><div>A microsimulation model was built to reflect the care pathway, using individual-level data from the National Lung Screening Trial individual-level data, and aggregated data from the literature. The model includes a simulation of the detection of the Big-3 diseases through screening and standard of care. The model also simulated tumor growth and the effects of smoking cessation and treatment. Hypothetical (former) smokers (aged 55–74 y) were simulated according to the National Lung Screening Trial criteria. Individuals with screening-detected diseases receiving (preventative) treatment experience a reduced risk of events and increased survival. A Dutch health system perspective and lifetime horizon were adopted.</div></div><div><h3>Results</h3><div>Simultaneous LC and CVD screening was the most cost-effective, with incremental costs and effects of €1937 and 0.22 quality-adjusted life-years (QALYs) versus no screening, and €595 and 0.08 QALYs versus LC screening, respectively. This yielded incremental cost-utility ratios of €8561 per QALY and €7154 per QALY versus no screening and LC screening, respectively. LC plus COPD screening was dominated by LC + CVD screening, which yielded lower health benefits and higher costs.</div></div><div><h3>Conclusions</h3><div>Simultaneous screening for LC + CVD in a high-risk population offers health benefits at low costs compared with no screening or LC screening alone. Adding COPD screening cannot yet be justified owing to the limited clinical evidence.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100813"},"PeriodicalIF":3.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yttrium-90 Radioembolization for Hepatic Metastases Secondary to Thymic Malignancies: A Case Report","authors":"Gavin Yuan BA,&nbsp;Elena N. Petre MD,&nbsp;Etay Ziv MD, PhD,&nbsp;Brett Marinelli MD,&nbsp;Ken Zhao MD,&nbsp;Vlasios Sotirchos MD,&nbsp;Erica S. Alexander MD","doi":"10.1016/j.jtocrr.2025.100812","DOIUrl":"10.1016/j.jtocrr.2025.100812","url":null,"abstract":"<div><div>The current guidelines for the treatment of extrathoracic metastases secondary to thymic neoplasms recommend chemotherapy. Thymic carcinomas are radiosensitive, and radiation therapy is recommended for intrathoracic masses and isolated metastases that are not amenable to resection. Liver-directed therapy, particularly yttrium-90 radioembolization, has been used for the treatment of oligometastatic diseases in the liver from various primaries. Here, we report three cases of radioembolization for the treatment of thymic carcinoma that metastasized to the liver.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100812"},"PeriodicalIF":3.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143768436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC","authors":"Federico Cappuzzo MD ,&nbsp;Zanete Zvirbule MD ,&nbsp;Ernesto Korbenfeld MD ,&nbsp;Jaroslaw Kolb-Sielecki MD ,&nbsp;Dolores Isla MD, PhD ,&nbsp;Aleksandra Szczesna MD, PhD ,&nbsp;Amparo Yovanna Castro Sanchez PhD ,&nbsp;Alberto Bustillos MD ,&nbsp;Xiaoyan Liu PhD ,&nbsp;Fiona Young MbChB ,&nbsp;Nadia Tosti PhD ,&nbsp;Marta Freitas Monteiro MSc, PhD ,&nbsp;Margarita Majem MD, PhD","doi":"10.1016/j.jtocrr.2025.100815","DOIUrl":"10.1016/j.jtocrr.2025.100815","url":null,"abstract":"<div><h3>Introduction</h3><div>Subcutaneous (SC) atezolizumab, a co-formulation containing atezolizumab and recombinant human hyaluronidase PH20), has been approved for use in more than 50 countries for the same indications as intravenous (IV) atezolizumab. IMscin002 (NCT05171777), a phase 2, randomized, open-label, crossover trial, investigated patient preferences and health care professionals’ (HCPs’) perceptions of atezolizumab SC versus IV for the treatment of NSCLC; we report the primary results of IMscin002.</div></div><div><h3>Methods</h3><div>Patients with programmed death-ligand 1-positive resected NSCLC who had completed adjuvant chemotherapy without evidence of recurrence, and chemotherapy-naive patients with programmed death-ligand 1–high metastatic NSCLC were randomized 1:1 to arm A (atezolizumab SC then atezolizumab IV) or arm B (atezolizumab IV then atezolizumab SC). After cycle 3, patients switched administration routes. After cycle 6, the patients chose the route of administration for the continuation period. The primary end point was patient preference for SC or IV atezolizumab, and the secondary end points were patient- and HCP-reported outcomes and safety.</div></div><div><h3>Results</h3><div>A total of 179 patients were included in this study. Most patients (70.7%; n = 87 of 123) preferred SC atezolizumab over IV, with 79.4% (n = 85 of 107) choosing SC atezolizumab during the continuation period. Among the HCPs, 75.2% (n = 76 of 101) indicated that atezolizumab SC was more convenient than IV, and 77.8% (n = 77 of 99) strongly agreed or agreed that it would allow patients to spend less time in care units. No new or unexpected safety findings were identified, and switching between administration routes was well tolerated and managed.</div></div><div><h3>Conclusions</h3><div>Most patients preferred SC atezolizumab over IV. There were no new safety findings, and switching between the administration routes was well tolerated. These results support the preference for SC formulations to reduce the treatment burden.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 5","pages":"Article 100815"},"PeriodicalIF":3.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143800548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report","authors":"Aditi Singh MBBS, MPH ,&nbsp;Arthi Sridhar MBBS ,&nbsp;Aastha Poddar MBBS ,&nbsp;Anastasios Dimou MD ,&nbsp;Kaushal Parikh MBBS ,&nbsp;Mohamed Shanshal MD ,&nbsp;Anna Schwecke APRN, CNP, MS ,&nbsp;Nicole Moffett APRN, CNP, MSN ,&nbsp;Manish R. Patel DO ,&nbsp;Aaron S. Mansfield MD ,&nbsp;Konstantinos Leventakos MD, PhD","doi":"10.1016/j.jtocrr.2025.100807","DOIUrl":"10.1016/j.jtocrr.2025.100807","url":null,"abstract":"<div><div>Third-generation tyrosine kinase inhibitors are effective treatment of <em>EGFR</em>-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC, it is important to study treatment options that are safe and effective for this disease. In this case series, three patients received treatment with lurbinectedin plus osimertinib after transformation to SCLC. In our limited experience, the combination was found to be safe.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 6","pages":"Article 100807"},"PeriodicalIF":3.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143855988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}